• • Pipeline
  • Philosophy
  • RENCAREX®
    • Overview
    • About RCC
    • Therapeutic Target
    • Phase I & II
    • Phase III ARISER
    • Markets
  • REDECTANE®
    • Overview
    • Functionality
    • Proof-of-concept study
    • Phase III registration trial
    • Market
  • MESUPRON®
    • Overview
    • About Metastasis
    • Therapeutic Target
    • Phase I with WX-UK1
    • Phase I & II with MESU
  • WX-554
  • WX-037
  • Research Projects
  • Publications
  • For Patients
    • Ongoing clinical studies

WILEX AG - Focused Cancer Therapies | Grillparzerstr. 10, 81675 Munich | Germany | Tel. +49 (0)89 41 31 38 - 0 | Fax +49 (0)89 41 31 38 - 99

Imprint | Disclaimer | Privacy Policy © WILEX AG | RENCAREX®, REDECTANE® and MESUPRON® are registered trademarks.